BackLinike Medical Group Overview
Linike Medical Group Ltd

Linike Medical Group Return on Equity

Valuation check: LNMG's ROE is 2.99%, below the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

2.99%

Return on Equity

2.99%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Linike Medical Group (LNMG) FAQ

Linike Medical Group (LNMG) currently reports a ROE of 2.99%. That is below the sector sector average of 11.3%. Use the charts on this page to explore Linike Medical Group's ROE history and peer comparisons.

Linike Medical Group's ROE of 2.99% is lower than the its sector sector average of 11.3%. That is roughly 73.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Linike Medical Group's current 2.99% should be judged against industry norms (sector average: 11.3%) and against LNMG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2.99%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Linike Medical Group, and consider following LNMG for alerts when major investors trade the stock.

Questions & Answers